After Novartis walks on last STING drug, Chinook spits out orphan Aduro assets
In August, Chinook merged with the struggling Aduro to take on the company’s pipeline programs for kidney disease research. Monday, Chinook announced that Aduro will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
